Rima Sahay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rima Sahay has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alby John Varghese
Greater Chennai Corporation, Ripon Building, Chennai 600003, India
1 shared publication - Anita Shete-Aich
Maximum Containment Facility, ICMR—National Institute of Virology, Pune 411001, Maharashtra, India
1 shared publication - Augustine Durai Samy
Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
1 shared publication - Azhagendran Sivalingam
Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
1 shared publication - Chethrapilly Purushothaman Girish Kumar
ICMR National Institute of Epidemiology, Chennai, India
1 shared publication - Dhana Priya Vadhani Sekar
Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
1 shared publication
Latest Publications
- Open Access
Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
Open AccessEffectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.